Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M36,297Revenue $M2,105Net Margin (%)15.9Z-Score22.2
Enterprise Value $M36,548EPS $3.8Operating Margin %34.3F-Score4
P/E(ttm))99.2Cash Flow Per Share $-2.0Pre-tax Margin (%)32.1Higher ROA y-yN
Price/Book15.410-y EBITDA Growth Rate %0Quick Ratio5.1Cash flow > EarningsY
Price/Sales16.25-y EBITDA Growth Rate %0Current Ratio5.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %35.2ROA % (ttm)13.5Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)20.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M101ROI % (ttm)53.3Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 355.520%Add 60.34%2,795,500
REGNFrank Sands 2014-06-30 Add0.64%$277.29 - $313.74
($296.6)
$ 355.520%Add 22.32%4,907,362
REGNRay Dalio 2014-06-30 Buy 0.04%$277.29 - $313.74
($296.6)
$ 355.520%New holding, 18400 sh.18,400
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 355.520%New holding, 881 sh.881
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 355.520%New holding, 2295 sh.2,295
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 355.516%Add 23.47%1,743,468
REGNFrank Sands 2014-03-31 Add0.22%$267.62 - $347.62
($307.2)
$ 355.516%Add 7.48%4,012,062
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 355.516%New holding, 6084 sh.6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 355.524%Sold Out0
REGNFrank Sands 2013-09-30 Add0.56%$227.65 - $309.174
($262.76)
$ 355.535%Add 20.34%3,777,357
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 355.535%New holding, 3285 sh.3,285
REGNRay Dalio 2013-09-30 Sold Out -0.01%$227.65 - $309.174
($262.76)
$ 355.535%Sold Out0
REGNFrank Sands 2013-06-30 Add1.07%$178.51 - $282.8
($232.86)
$ 355.553%Add 81.03%3,138,793
REGNRay Dalio 2013-06-30 Buy 0.01%$178.51 - $282.8
($232.86)
$ 355.553%New holding, 4100 sh.4,100
REGNVanguard Health Care Fund 2013-03-31 Add0.62%$158.42 - $183.77
($171.66)
$ 355.5107%Add 170.41%1,412,100
REGNFrank Sands 2013-03-31 Reduce-1.02%$158.42 - $183.77
($171.66)
$ 355.5107%Reduce -46.22%1,733,896
REGNFrank Sands 2012-09-30 Reduce-1.2%$112.77 - $152.66
($135.2)
$ 355.5163%Reduce -37.57%3,834,373
REGNVanguard Health Care Fund 2012-09-30 Reduce-0.09%$112.77 - $152.66
($135.2)
$ 355.5163%Reduce -24.56%522,200
REGNFrank Sands 2012-06-30 Add0.2%$108.78 - $143.87
($125.43)
$ 355.5183%Add 6.5%6,142,048
REGNDodge & Cox 2012-03-31 Sold Out $57.83 - $119.96
($92.23)
$ 355.5285%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
REGN Mario Gabelli 2014-06-302,29500New Buy
REGN Ray Dalio 2014-06-3018,4000.020.04New Buy
REGN Joel Greenblatt 2014-06-3088100New Buy
REGN Vanguard Health Care Fund 2014-06-302,795,5002.772.1+60.34%
REGN Frank Sands 2014-06-304,907,3624.863.5+22.32%
REGN Ron Baron 2014-06-307,1090.010.01+16.85%
Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-09-16Buy31,717$349.262.39view
Sanofi10% Owner 2014-09-15Buy140,632$345.153.61view
VAGELOS P ROYChairman of the Board 2014-09-10Sell10,328$350.072.15view
GOLDSTEIN JOSEPH LDirector 2014-08-27Sell2,000$350.312.08view
Tessier-Lavigne MarcDirector 2014-08-27Sell3,000$352.21.53view
Aberman Michael SVP Strategy and Investor Relat 2014-08-19Sell3,611$3502.17view
McCorkle Douglas SVP Controller and Asst Treasur 2014-08-18Sell5,875$3531.3view
BROWN MICHAEL SDirector 2014-08-15Sell3,000$349.22.41view
GOLDSTEIN JOSEPH LDirector 2014-08-14Sell2,000$347.652.86view
VAGELOS P ROYChairman of the Board 2014-08-13Sell8,028$340.015.17view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 
    Weekly Top Insider Sells: REGN May 27 2013 
    comment on REGN Mar 06 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
    Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
    52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 


    More From Other Websites
    [video] Biotech selloff: What to buy Sep 25 2014
    Biotech selloff: What to buy Sep 25 2014
    The Zacks Analyst Blog Highlights: Auxilium Pharmaceuticals, QLT, Endo International, Gilead and... Sep 25 2014
    [video] Cramer's favorite large cap biotech plays Sep 24 2014
    Cramer's favorite large cap biotech plays Sep 24 2014
    Acorda To Buy Civitas, Gains Parkinson's Disease Drug Sep 24 2014
    Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA Sep 24 2014
    Anacor's Kerydin Launched in the US for Onychomycosis Sep 23 2014
    Bayer/Regeneron Successfully Expand Eylea Label in Japan Sep 23 2014
    Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with... Sep 22 2014
    The Zacks Analyst Blog Highlights: Google, Facebook, Apple, Microsoft and Regeneron Pharmaceuticals Sep 18 2014
    Regeneron Gets Breakthrough Therapy Status for Eylea Sep 17 2014
    Stocks Erase Modest Gains; Netflix Gaps Below 50-Day Line Sep 16 2014
    EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic... Sep 16 2014
    Biotech still place to be: Pro Sep 15 2014
    [video] Biotech still place to be: Pro Sep 15 2014
    US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
    Stocks Show Modest Losses; Biotechs Pressured Again Sep 11 2014
    Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs Sep 11 2014
    Like Apple, these firms satisfy unmet need: Cramer Sep 10 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK